Gastroenterology prior authorization at Geisinger Health Plan
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Geisinger Health Plan gastroenterology PA at a glance
Geisinger Health Plan reviews gastroenterology PA submissions against its medical policy library, with rules drawn primarily from AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target. Geisinger Health Plan-specific context: Integrated payer-provider system in central/northeast Pennsylvania (~600K members). Acquired by Kaiser-affiliated Risant Health in March 2024 — operational integration ongoing. PA Insurance Department oversight. Strong MA presence in service area.
Documentation packet — what to send
- IBD diagnosis confirmed by endoscopy/biopsy
- Disease distribution and severity
- Prior conventional therapies tried
- Steroid course (drug, dose, taper attempts)
- Therapeutic drug monitoring labs where applicable
- Tuberculosis + hepatitis B screening prior to biologic
Common denial patterns to pre-empt
Patterns observed in gastroenterology across payers, and where Geisinger Health Plan's book of business overlaps:
- Step therapy through 5-ASA / immunomodulators / steroids first
- Switching between mechanism-of-action classes without documented failure
- Therapeutic drug monitoring not done before dose escalation
- Endoscopic disease not documented
- Medicare Advantage step therapy on Part B drugs
Appeal angles when Geisinger Health Plan denies
- AGA / ACG guidelines for IBD positioning
- Endoscopic Mayo subscore or SES-CD documenting active disease
- Failure of prior biologic by mechanism of action (anti-TNF, anti-integrin, anti-IL-12/23, JAK)
- Steroid-dependence or steroid-refractory disease
Peer-to-peer prep
- Pull the most recent endoscopy report with photos if possible
- Quantify steroid dependence (mg of prednisone per year, taper attempts)
- Reference STRIDE-II treat-to-target if requesting mechanism switch
- Cite specific endoscopic scoring (Mayo, SES-CD) and the date
Drug-specific PA criteria at Geisinger Health Plan
Deep dives on each drug's PA criteria at Geisinger Health Plan:
Frequently asked questions
What documentation does Geisinger Health Plan need for gastroenterology prior authorizations?
Geisinger Health Plan's PA packet for gastroenterology typically includes: IBD diagnosis confirmed by endoscopy/biopsy; Disease distribution and severity; Prior conventional therapies tried; Steroid course (drug, dose, taper attempts). AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target citations strengthen the submission.
What's the turnaround at Geisinger Health Plan?
Geisinger Health Plan standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which gastroenterology drugs does Geisinger Health Plan most often PA-restrict?
Top targets in gastroenterology: adalimumab, infliximab, ustekinumab, risankizumab, tofacitinib. Each follows the per-drug step therapy + documentation requirements published in Geisinger Health Plan's medical policy library.
How do I prep a peer-to-peer with Geisinger Health Plan in gastroenterology?
Pull the most recent endoscopy report with photos if possible Quantify steroid dependence (mg of prednisone per year, taper attempts) Have the policy URL and the patient's chart open before the call.
Generate a Gastroenterology PA packet
Open ApprovalHelp — generate a gastroenterology PA packet tailored to Geisinger Health Plan's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com